<p><strong>Background:</strong> Mainstreaming cancer genetics may be an option to improve access to genetic testing in most parts of Asia, including Malaysia. The MaGiC study is conducted to study the feasibility of mainstreaming and the psychosocial impact of BRCA testing in ovarian cancer patients in Malaysia. The study participants are recruited via the traditional genetics pathway where patients are counselled by the clinical geneticists or genetic counsellors or <em>via</em> the mainstreaming pathway where the patients are counselled by non-genetics clinicians. <strong>Methods:</strong> This is a prospective observational study of 800 patients with non-mucinous ovarian cancer irrespective of family history. Questionnaires were conducte...
Background: this prospective multi-centre UK study assesses the impact of predictive genetic testing...
BACKGROUND: Current practice for patients with breast cancer referred for genetic counseling, includ...
Hereditary breast and/or ovarian cancer (HBOC) accounts for 5-10% of all breast and ovarian cancer d...
<p><strong>Introduction: </strong>Identifying germline BRCA mutations in ovarian cancer patients is ...
Genetic counseling (GC) and genetic testing are vital risk management strategies in hereditary breas...
Objective: Pathogenic BRCA variants account for between 5.8-24.8% of ovarian cancers. The identifica...
Decreasing costs of genetic testing and advances in treatment for women with cancer with germline $\...
Background: Reflex (automatic) BRCA1/2 tumour genetic testing of all newly diagnosed high-grade sero...
Background: BRCA1/2 mutation status has increasing relevance for ovarian cancer treatments, making t...
Poster P117pp. e284–e319 of this journal issue entitled: Proffered papers and posters presented at t...
The final publication is available at Springer via http://dx.doi.org/10.1007/s10897-017-0108-5Decrea...
This study compares knowledge, experience and understanding of genetic testing, and psychological ou...
It remains uncertain whether members of hereditary breast and ovarian cancer (HBOC) families experie...
It remains uncertain whether members of hereditary breast and ovarian cancer (HBOC) families experie...
BACKGROUND: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more ...
Background: this prospective multi-centre UK study assesses the impact of predictive genetic testing...
BACKGROUND: Current practice for patients with breast cancer referred for genetic counseling, includ...
Hereditary breast and/or ovarian cancer (HBOC) accounts for 5-10% of all breast and ovarian cancer d...
<p><strong>Introduction: </strong>Identifying germline BRCA mutations in ovarian cancer patients is ...
Genetic counseling (GC) and genetic testing are vital risk management strategies in hereditary breas...
Objective: Pathogenic BRCA variants account for between 5.8-24.8% of ovarian cancers. The identifica...
Decreasing costs of genetic testing and advances in treatment for women with cancer with germline $\...
Background: Reflex (automatic) BRCA1/2 tumour genetic testing of all newly diagnosed high-grade sero...
Background: BRCA1/2 mutation status has increasing relevance for ovarian cancer treatments, making t...
Poster P117pp. e284–e319 of this journal issue entitled: Proffered papers and posters presented at t...
The final publication is available at Springer via http://dx.doi.org/10.1007/s10897-017-0108-5Decrea...
This study compares knowledge, experience and understanding of genetic testing, and psychological ou...
It remains uncertain whether members of hereditary breast and ovarian cancer (HBOC) families experie...
It remains uncertain whether members of hereditary breast and ovarian cancer (HBOC) families experie...
BACKGROUND: Over recent years genetic testing for germline mutations in BRCA1/BRCA2 has become more ...
Background: this prospective multi-centre UK study assesses the impact of predictive genetic testing...
BACKGROUND: Current practice for patients with breast cancer referred for genetic counseling, includ...
Hereditary breast and/or ovarian cancer (HBOC) accounts for 5-10% of all breast and ovarian cancer d...